Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 3098542, 9 pages
https://doi.org/10.1155/2017/3098542
Research Article

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients

1Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
2Department of Gynecologic Oncology, Institute for Cancer Genetics and Informatics and University of Oslo, Oslo, Norway
3MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK
4DOCs International, Buckinghamshire, UK
5Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
7Medical Oncology, Royal Prince Alfred Hospital and Concord Repatriation General Hospital and Chris O’Brien Lifehouse, Sydney, NSW, Australia
8Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

Correspondence should be addressed to Åslaug Helland; on.oiu.nisidem@dnalleha

Received 14 November 2016; Accepted 11 January 2017; Published 15 February 2017

Academic Editor: Ines Zidi

Copyright © 2017 Ann Rita Halvorsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Baldwin, B. Huang, R. W. Miller et al., “Ten-year relative survival for epithelial ovarian cancer,” Obstetrics and Gynecology, vol. 120, no. 3, pp. 612–618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Meinhold-Heerlein, C. Fotopoulou, P. Harter et al., “Statement by the kommission ovar of the AGO: the new FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal cancer,” Geburtshilfe und Frauenheilkunde, vol. 75, no. 10, pp. 1021–1027, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. D. I. R. Holmes and I. Zachary, “The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease,” Genome Biology, vol. 6, no. 2, article no. 209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C.-H. Heldin, K. Rubin, K. Pietras, and A. Östman, “High interstitial fluid pressure—an obstacle in cancer therapy,” Nature Reviews Cancer, vol. 4, no. 10, pp. 806–813, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Ferrara, K. J. Hillan, H.-P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. R. K. Jain, D. G. Duda, J. W. Clark, and J. S. Loeffler, “Lessons from phase III clinical trials on anti-VEGF therapy for cancer,” Nature Clinical Practice Oncology, vol. 3, no. 1, pp. 24–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Oza, A. D. Cook, J. Pfisterer et al., “Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial,” The Lancet Oncology, vol. 16, no. 8, pp. 928–936, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Kinose, K. Sawada, K. Nakamura, and T. Kimura, “The role of microRNAs in ovarian cancer,” BioMed Research International, vol. 2014, Article ID 249393, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Hayes, P. P. Peruzzi, and S. Lawler, “MicroRNAs in cancer: biomarkers, functions and therapy,” Trends in Molecular Medicine, vol. 20, no. 8, pp. 460–469, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Weber, D. H. Baxter, S. Zhang et al., “The microRNA spectrum in 12 body fluids,” Clinical Chemistry, vol. 56, no. 11, pp. 1733–1741, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. D. Arroyo, J. R. Chevillet, E. M. Kroh et al., “Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5003–5008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513–10518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Vecchione, B. Belletti, F. Lovat et al., “A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 24, pp. 9845–9850, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Y.-W. Kim, E. Y. Kim, D. Jeon et al., “Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,” Drug Design, Development and Therapy, vol. 8, pp. 293–314, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Mestdagh, P. Van Vlierberghe, A. De Weer et al., “A novel and universal method for microRNA RT-qPCR data normalization,” Genome Biology, vol. 10, no. 6, article R64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Wylie, J. Shelton, A. Choudhary, and A. T. Adai, “A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data,” BMC Research Notes, vol. 4, article 555, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Ståhlberg, V. Rusnakova, and M. Kubista, “The added value of single-cell gene expression profiling,” Briefings in Functional Genomics, vol. 12, no. 2, pp. 81–89, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Dysvik and I. Jonassen, “J-Express: exploring gene expression data using Java,” Bioinformatics, vol. 17, no. 4, pp. 369–370, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. T. D. Schmittgen, E. J. Lee, J. Jiang et al., “Real-time PCR quantification of precursor and mature microRNA,” Methods, vol. 44, no. 1, pp. 31–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. P. Prahm, G. W. Novotny, C. Høgdall, and E. Høgdall, “Current status on microRNAs as biomarkers for ovarian cancer,” APMIS, vol. 124, no. 5, pp. 337–355, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Chen, L. Zhang, and Q. Hao, “Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation,” Cancer Cell International, vol. 13, no. 1, article 86, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. D. Taylor and C. Gercel-Taylor, “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer,” Gynecologic Oncology, vol. 110, no. 1, pp. 13–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Zuberi, R. Mir, J. Das et al., “Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features,” Clinical and Translational Oncology, vol. 17, no. 10, pp. 779–787, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Maierthaler, A. Benner, M. Hoffmeister et al., “Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer,” International Journal of Cancer, vol. 140, no. 1, pp. 176–187, 2017. View at Publisher · View at Google Scholar
  25. R. Tejero, A. Navarro, M. Campayo et al., “MiR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma,” PLoS ONE, vol. 9, no. 7, Article ID e101899, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Shapira, M. Oswald, J. Lovecchio et al., “Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes,” British Journal of Cancer, vol. 110, no. 4, pp. 976–983, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Fromm, T. Billipp, L. E. Peck et al., “A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome,” Annual Review of Genetics, vol. 49, pp. 213–242, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. N. C. T. Schopman, S. Heynen, J. Haasnoot, and B. Berkhout, “A miRNA-tRNA mix-up: tRNA origin of proposed miRNA,” RNA Biology, vol. 7, no. 5, pp. 573–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Anderson and P. Ivanov, “TRNA fragments in human health and disease,” FEBS Letters, vol. 588, no. 23, pp. 4297–4304, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Guzman, K. Agarwal, D. Asthagiri et al., “Breast cancer-specific miR signature unique to extracellular vesicles includes “microRNA-like” tRNA fragments,” Molecular Cancer Research, vol. 13, no. 5, pp. 891–901, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. P. A. Gregory, C. P. Bracken, A. G. Bert, and G. J. Goodall, “MicroRNAs as regulators of epithelial-mesenchymal transition,” Cell Cycle, vol. 7, no. 20, pp. 3112–3117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Li, B. Li, D. Chen et al., “miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis,” Oncology Reports, vol. 34, no. 1, pp. 51–58, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Humphries and C. Yang, “The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy,” Oncotarget, vol. 6, no. 9, pp. 6472–6498, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. J. K. Chan, T. K. Kiet, K. Blansit et al., “MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer,” Gynecologic Oncology, vol. 133, no. 3, pp. 568–574, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Petrillo, G. F. Zannoni, L. Beltrame et al., “Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies,” Annals of Oncology, vol. 27, no. 4, Article ID mdw007, pp. 625–634, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. T. F. Hansen, A. L. Carlsen, N. H. H. Heegaard, F. B. Sørensen, and A. Jakobsen, “Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer,” British Journal of Cancer, vol. 112, no. 4, pp. 624–629, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. N. B. La Thangue and D. J. Kerr, “Predictive biomarkers: a paradigm shift towards personalized cancer medicine,” Nature Reviews Clinical Oncology, vol. 8, no. 10, pp. 587–596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. P.-E. Colombo, M. Fabbro, C. Theillet, F. Bibeau, P. Rouanet, and I. Ray-Coquard, “Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer,” Critical Reviews in Oncology/Hematology, vol. 89, no. 2, pp. 207–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Meric-Bernstam, C. Farhangfar, J. Mendelsohn, and G. B. Mills, “Building a personalized medicine infrastructure at a major cancer center,” Journal of Clinical Oncology, vol. 31, no. 15, pp. 1849–1857, 2013. View at Publisher · View at Google Scholar · View at Scopus